SCHEMBL4933617

SCHEMBL4933617

CC(c1nc2ccccc2[nH]1)N1CCCCCC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 4/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KLK7 P49862 1/20 0.43
IDO1 P14902 1/20 0.42
POLB P06746 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
HTT P42858 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4933877 0.80 BCHE (0.53) LMNASMN1; SMN2BCHEACHEALDH1A1
SCHEMBL28722124 0.78 MAPT (0.52) LMNASMN1; SMN2BCHEACHEALDH1A1
SCHEMBL4728480 0.74 DRD4 (0.55) LMNASMN1; SMN2ALDH1A1KMT2AMAPT
SCHEMBL4929684 0.70 MAPT (0.50) LMNASMN1; SMN2BCHEACHEALDH1A1
SCHEMBL19741641 0.70 CHRM2 (0.49) SMN1; SMN2ALDH1A1KMT2AMAPTHPGD
SCHEMBL16070776 0.70 CHRM2 (0.49) SMN1; SMN2ALDH1A1KMT2AMAPTHPGD
SCHEMBL10672122 0.70 CHRM2 (0.49) SMN1; SMN2ALDH1A1KMT2AMAPTHPGD
SCHEMBL524001 0.68 TAAR1 (0.68) LMNASMN1; SMN2ALDH1A1KMT2AKDM4E
SCHEMBL6244544 0.68 POLB (0.61) LMNASMN1; SMN2ALDH1A1KMT2AKDM4E
SCHEMBL12737571 0.68 TAAR1 (0.68) LMNASMN1; SMN2ALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS EFREMOV IVAN 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS PAICS, TMBIM6, ABCG2 LMNA 2469/4885SMN1; SMN2 478/4885BCHE 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.